(CercleFinance.com) – Valneva announced, at the very end of last week, the publication of new mixed data from a small exploratory study on the use as a heterologous booster of its inactivated vaccine against Covid-19, VLA2001.
According to these data, a booster dose was well tolerated in participants previously vaccinated with Pfizer-BioNTech or Moderna products, confirming the favorable safety profile of VLA2001, whether with a homologous or heterologous booster.
In contrast, the French vaccine company reports that, in this study, a booster dose with its product generated only a marginal increase in the neutralizing antibody response.
Valneva is currently seeking regulatory clearance for VLA2001 as a homologous and heterologous booster in individuals previously vaccinated with AstraZeneca’s ChAdOx1-S.